US Patent Office Issues Patent for USMI’s Cold Atmospheric Plasma for the Treatment of Cancer

Jun 14, 2018

TAKOMA PARK, Md.–(BUSINESS WIRE)–US Medical Innovations, LLC (USMI), a U.S. FDA registered life science and biomedical device company, and subsidiary of US Patent Innovations, LLC (USPI), announced today that the United States Patent Office (USPO) is issuing to the company Patent No. 9,999.452 B2 for their Cold Atmospheric Plasma (CAP) technology “Integrated Cold Plasma and High Frequency Plasma Electrosurgical System and Method” for use in the treatment of cancer therapy.

USMI is the first company in the world to integrate a high frequency electrosurgical generator and plasma gas to deliver a Cold Atmospheric Plasma (CAP) for the selective treatment of cancer. This novel process for using CAP technology is being developed for use during surgery. It has been reported that CAP selectively ablates cancer cells without damaging healthy human tissue. The CAP effect has shown to cause significant stress to cancer cells that drastically decreases the cell’s viability, while healthy human cells remain unharmed.

Utilizing USMI’s patented electrosurgical plasma system, CAP is delivered through the Canady Helios™ Plasma Scalpel. This new technology was developed by Dr. Jerome Canady and his team at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI/ABTS) in conjunction with Michael Keidar PhD, Director of George Washington University’s (GWU) and USMI Plasma Medicine Program, Alex Shashurin, PhD, Purdue University and Taisen Zhuang, PhD VP Research & Development USMI.

Dr. Michael Keidar said, “this approach allows removal of tumor and treatment of surgical margins for ablating cancer cells using a single device.” Dr. Keidar added that a multiinstitutional clinical trial will start this summer.

Jerome Canady, M.D., CEO at USMI, and Co-Director of the GWU Plasma Medicine Program commented, “After the surgeon removes the cancerous tumor, CAP is subsequently sprayed at the surgical margins to ablate any remaining cancerous tissue or cells, thus reducing the chances of cancer recurrence. We see our CAP treatment as an important adjunct to the current treatment protocol for solid cancerous tumors. Our new plasma devices will change the landscape of electrosurgery and cancer therapy as well as offer cancer patients new hope in the very near-future.”

About US Medical Innovations

US Medical Innovations, LLC (USMI), based out of Takoma Park, MD, is a privately-held FDA registered life science and biomedical device company. USMI is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives. Leveraging the insights of USMI’s CEO and Co-Founder, as both a transplant surgeon and inventor, Dr. Canady continues to transition USMI to a Life Science company by investing its R&D in cancer therapies and robotics. For more information on US Medical Innovation’s products and technology please visit:

US Medical Innovations, LLC
Kenniah Chestnut, Esq.